Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib With or Without Chemotherapy in EGFR-Mutant BIM-Deleted NSCLC
NCT03002844Phase 2Unknown
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03002844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002844.